Evaluating the Association between Clinical Characteristics with Progression-Free Survival and 3-Year Survival in Patients with Epithelial Ovarian Cancer

Brahmana Askandar Tjokroprawiro, Sonny Fadli, Budiono Budiono


Background: This study was conducted to determine the association between clinical characteristics, progression-free survival (PFS), and 3-year survival in patients with epithelial ovarian cancer who underwent surgery in 2016-2017 at RSUD Dr. Soetomo. This study was carried out with the hope of contributing to services for patients with epithelial ovarian cancer to improve outcomes at RSUD Dr. Soetomo. 

Methods: This retrospective analytic study used medical record data. Survival analysis was done employing Kaplan-Meier and log-rank tests, while Cox regression was utilized to analyze characteristics, recurrence, and mortality.

Results: In 2016-2017, 56 patients with epithelial ovarian cancer met the inclusion criteria. Clinical characteristics of residue, stage had significant associations with PFS (P-value of 0.007 and P-value of 0.005, respectively). Residue, stage, histopathology, and the number of chemotherapy cycles had significant associations with 3-year survival (P-value of 0.001, P-value of < 0.001, P-value of < 0.001, P-value of 0.031, respectively). Recurrence and stage had a significant association with the following hazard ratios: stage I HR: 1 (CI 95%, P-value 0.145), stage II HR: 6.5 (CI 95% 0.6–74.7, P-value 0.134), stage III HR: 12.2 (CI 95% 1.4–105.4, P-value 0.061), and stage IV HR: 10.4 (CI 95% 0.8–120.8, P-value 0.061). Mortality had significant associations with stage, histopathology, and the number of chemotherapy cycles, with hazard ratios as follows: stage IV HR: 43.6 (CI 95% 4.5–417.9, P-value 0.001), seromucinous histopathology HR: 20.1 (CI 95% 0.9–408.6, P-value 0.026), chemotherapy cycles < 3 HR: 3.6 (CI 95% 1.2–11.5, P-value 0.459), and > 3 HR: 1 (CI 95%, P-value 0.028).

Conclusions: Residue and stage had statistically significant associations with PFS and can be predictors for disease recurrence. Residue, stage, histopathology, number of chemotherapy cycles had significant associations with 3-year survival, but only the latter three characteristics can be predictors for mortality


ovarian cancer, progression-free survival, 3-year survival


Sung H, Ferlay J, Siegel RL, et al. Global cancer

statistics 2020: GLOBOCAN estimates of incidence

and mortality worldwide for 36 cancers in 185

countries. CA Cancer J Clin. 2021;71(3):209–249.

Howlader N, Noone AM, Krapcho M, et al. SEER

Cancer Statistics Review, 1975-2017 [Internet]. Bethesda: National Cancer Institute; 2020 [cited 2021 Jan 30]. Available from: https://seer.cancer.gov/csr/1975–2017/

Ayuningtyas A, Hartono P, Nugroho H. Characteristic

of ovarian cancer deaths in Dr. Soetomo Hospital

during 2015-2017. In: Case Presentation, Department

of Obstetric Gynecology, Faculty of Medicine, Universitas Airlangga, RSUD dr. Soetomo, Surabaya;

p. 1–2. Progression-Free Survival and 3-Year Survival in Patients with Epithelial Ovarian Cancer Brahmana A skandar, ET A L

Meinhold-Heerlein I, Fotopoulou C, Harter P, et al.

The new WHO classification of ovarian, fallopian

tube, and primary peritoneal cancer and its clinical

implications. Arch Gynecol Obstet. 2016;293(4):695–

Prat J; FIGO Committee on Gynecologic Oncology.

FIGO’s staging classification for cancer of the ovary,

fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87-9.

Winter WE, Maxwell GL, Tian C, et al. Gynecologic

Oncology Group Study. Prognostic factors for stage

III epithelial ovarian cancer: a Gynecologic Oncology

Group Study. J Clin Oncol. 2007;25(24):3621–7.

Bailey J, Murdoch J, Anderson R, et al. Stage III

and IV ovarian cancer in the South West of England:

five-year outcome analysis for cases treated in 1998.

Int J Gynecol Cancer. 2006;16 Suppl 1:25–9.

Aziz KKA, Shehata MA, Ghany AEA, et al.

Retrospective study of epithelial ovarian cancer in

the Oncology Department, Menoufia University.

Menoufia Med J. 2014;27(4):650.

Marszalek A, Alran S, Scholl S, et al. Outcome in advanced ovarian cancer following an appropriate and comprehensive effort at upfront cytoreduction: a twenty-year experience in a single cancer institute. Int J Surg Oncol. 2010;2010:214919.

O’Malley CD, Cress RD, Campleman SL, Leiserowitz

GS. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol. 2003;91(3):608–15.

Oliver KE, Brady WE, Birrer M, et al. An evaluation

of progression free survival and overall survival of

ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017;147(2):243–249.

Chang LC, Huang CF, Lai MS, et al. Prognostic factors

in epithelial ovarian cancer: A population-based study. PLoS One. 2018;13(3):e0194993.

Eisenkop SM, Friedman RL, Wang HJ. Complete

cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69(2):103–8.

Chan JK, Loizzi V, Lin YG, et al. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?. Obstet Gynecol. 2003;102(1):156–61.

Noela F, Nuryanto KH. Epidemiology data of ovarian

cancer in Dr. Cipto Mangunkusumo Hospital, Jakarta.

Indones J Obstet Gynecol. 2016;4(2):101.

Full Text: PDF

DOI: 10.33371/ijoc.v15i4.815

Article Metrics

Abstract view : 48 times
PDF - 27 times


  • There are currently no refbacks.

Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.